Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 EPIDEMIOLOGY BASED MODELLING
2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 CHALLENGES
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
5.1 PESTEL ANALYSIS
5.2 PORTER’S 5 FORCES MODEL
5.3 STRATEGIC INITIATIVES
6 EPIDEMIOLOGY
6.1 DISEASE PREVALENCE BY COUNTRY
6.2 DISEASE INCIDENCE BY COUNTRY
6.3 RISK FACTORS
(FACTORS THAT INCREASE THE LIKELIHOOD OF DEVELOPING A DISEASE, SUCH AS AGE, GENDER, LIFESTYLE FACTORS, ENVIRONMENTAL EXPOSURES, AND GENETIC PREDISPOSITION)
6.4 HEALTHCARE UTILIZATION
(HOW THE DISEASE AFFECTS HEALTHCARE UTILIZATION, SUCH AS HOSPITALIZATIONS, EMERGENCY ROOM VISITS, AND OUTPATIENT VISITS)
7 REGULATORY FRAMEWORK
7.1 REGULATORY APPROVAL PROCESS
7.2 GEOGRAPHIES’ EASE OF REGULATORY APPROVAL
7.3 REGULATORY APPROVAL PATHWAYS
7.4 LICENSING AND REGISTRATION
7.5 POST-MARKETING SURVEILLANCE
7.6 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES
8 PIPELINE ANALYSIS
8.1 CLINICAL TRIAL STATUS
8.1.1 CANDIDATE/AGENT
8.1.2 PROPERTIES
8.1.3 COMPANY NAME
8.1.4 THERAPEUTIC AREA
8.1.5 PRODUCT NAME
8.1.6 GENERIC NAME
8.1.7 TYPE
8.1.8 RESEARCH CODE
8.1.9 INDICATION
8.1.10 ORIGINATOR
8.1.11 SPONSOR
8.1.12 COLLABORATOR
8.1.13 LICENSOR
8.1.14 LICENSEE
8.2 DISTRIBUTION OF PRODUCTS BY PHASE
8.2.1 PRECLINICAL/RESEARCH PROJECT
8.2.2 PHASE I
8.2.3 PHASE II
8.2.4 PHASE III
8.2.5 PHSE IV
8.3 NUMBER OF SUBJECTS IN CLINICAL TRIALS
8.3.1 PHASE I
8.3.2 PHASE II
8.3.3 PHASE III
8.4 DISTRIBUTION OF PRODUCTS AND PROJECTS BY PHASE
8.4.1 PRECLINICAL/RESEARCH PROJECT
8.4.2 PHASE I
8.4.3 PHASE II
8.4.4 PHASE III
8.4.5 PHASE IV
8.5 DISTRIBUTION OF PROJECTS BY THERAPEUTIC AREA AND PHASE
8.5.1 PRECLINICAL/RESEARCH PROJECT
8.5.2 PHASE I
8.5.3 PHASE II
8.5.4 PHASE III
8.5.5 PHASE IV
8.6 DISTRIBUTION OF PROJECTS BY SCIENTIFIC APPROACH AND PHASE
8.6.1 PRECLINICAL/RESEARCH PROJECT
8.6.2 PHASE I
8.6.3 PHASE II
8.6.4 PHASE III
8.6.5 PHASE IV
9 MARKETED DRUG ANALYSIS
9.1 DRUG
9.1.1 BRAND NAME
9.1.2 GENERICS NAME
9.2 THERAPEUTIC INDIACTION
9.3 PHARACOLOGICAL CLASS OD THE DRUG
9.4 DRUG PRIMARY INDICATION
9.5 MARKET STATUS
9.6 MEDICATION TYPE
9.7 DRUG DOSAGES FORM
9.8 DOSAGES AVAILABILITY
9.9 PACKAGING TYPE
9.1 DRUG ROUTE OF ADMINISTRATION
9.11 DOSING FREQUENCY
9.12 DRUG INSIGHT
AN OVERVIEW OF THE DRUG DEVELOPMENT ACTIVITIES SUCH AS REGULATORY MILSTONE, SAFETY DATA AND EFFICACY DATA, MARKET EXCLUSIVITY DATA.
9.12.1 FORECAST MARKET OUTLOOK
9.12.2 CROSS COMPETITION
9.12.3 THERAPEUTIC PORTFOLIO
9.12.4 CURRENT DEVELOPMENT SCENARIO
10 MARKET ACCESS
10.1 10-YEAR MARKET FORECAST
10.2 CLINICAL TRIAL RECENT UPDATES
10.3 ANNUAL NEW FDA APPROVED DRUGS
10.4 DRUGS MANUFACTURER AND DEALS
10.5 MAJOR DRUG UPTAKE
10.6 CURRENT TREATMENT PRACTICES
10.7 IMPACT OF UPCOMING THERAPY
11 R & D ANALYSIS
11.1 COMPARATIVE ANALYSIS
11.2 DRUG DEVELOPMENTAL LANDSCAPE
11.3 IN-DEPTH INSIGHTS ON REGULATORY MILESTONES
11.4 THERAPEUTIC ASSESSMENT
11.5 ASSET-BASED COLLABORATIONS AND PARTNERSHIPS
12 PATENT ANALYSIS
12.1 PATENT LANDSCAPE
12.2 USPTO NUMBER
12.3 PATENT EXPIRY
12.3.1 US PATENT EXPIRY
12.3.2 EUROPE PATENT EXPIRY
12.4 EPIO NUMBER
12.5 PATENT STRENGTH AND QUALITY
12.6 PATENT CLAIMS
12.7 PATENT CITATIONS
12.8 PATENT LITIGATION AND LICENSING
12.9 FILE OF PATENT
12.1 PATENT RECEIVED CONTRIES
12.11 TECHNOLOGY BACKGROUND
13 COMPETITIVE INTELLIGENCE TRACKING DATA
13.1 CLINICAL TRIAL MONITORING ANALYSIS
13.2 REGULATORY AND COMMERCIAL MONITORING ANALYSIS
14 GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET, BY THERAPY TYPE
(NOTE: MARKET VALUE, MARKET VOLUME AND ASP WILL BE PROVIDED FOR ALL SEGMENTS AND SUB-SEGMENTS )
14.1 OVERVIEW
14.2 ENZYME REPLACEMENT THERAPY
14.2.1 IMIGLUCERASE
14.2.1.1. MARKET VALUE (USD MILLION)
14.2.1.2. MARKET VOLUME (UNITS)
14.2.1.3. AVERAGE SELLING PRICE (USD)
14.2.2 VELAGLUCERASE ALFA
14.2.2.1. MARKET VALUE (USD MILLION)
14.2.2.2. MARKET VOLUME (UNITS)
14.2.2.3. AVERAGE SELLING PRICE (USD)
14.2.3 TALIGLUCERASE ALFA
14.2.3.1. MARKET VALUE (USD MILLION)
14.2.3.2. MARKET VOLUME (UNITS)
14.2.3.3. AVERAGE SELLING PRICE (USD)
14.2.4 AGALSIDASE ALFA
14.2.4.1. MARKET VALUE (USD MILLION)
14.2.4.2. MARKET VOLUME (UNITS)
14.2.4.3. AVERAGE SELLING PRICE (USD)
14.2.5 AGALSIDASE BETA
14.2.5.1. MARKET VALUE (USD MILLION)
14.2.5.2. MARKET VOLUME (UNITS)
14.2.5.3. AVERAGE SELLING PRICE (USD)
14.2.6 ALGLUCOSIDASE ALFA
14.2.6.1. MARKET VALUE (USD MILLION)
14.2.6.2. MARKET VOLUME (UNITS)
14.2.6.3. AVERAGE SELLING PRICE (USD)
14.2.7 IDURSULFASE
14.2.7.1. MARKET VALUE (USD MILLION)
14.2.7.2. MARKET VOLUME (UNITS)
14.2.7.3. AVERAGE SELLING PRICE (USD)
14.2.8 GALSULFASE
14.2.8.1. MARKET VALUE (USD MILLION)
14.2.8.2. MARKET VOLUME (UNITS)
14.2.8.3. AVERAGE SELLING PRICE (USD)
14.2.9 ALDURAZYME
14.2.9.1. MARKET VALUE (USD MILLION)
14.2.9.2. MARKET VOLUME (UNITS)
14.2.9.3. AVERAGE SELLING PRICE (USD)
14.2.10 BETAINE
14.2.10.1. MARKET VALUE (USD MILLION)
14.2.10.2. MARKET VOLUME (UNITS)
14.2.10.3. AVERAGE SELLING PRICE (USD)
14.2.11 CYSTEAMINE
14.2.11.1. MARKET VALUE (USD MILLION)
14.2.11.2. MARKET VOLUME (UNITS)
14.2.11.3. AVERAGE SELLING PRICE (USD)
14.2.12 LARONIDASE
14.2.12.1. MARKET VALUE (USD MILLION)
14.2.12.2. MARKET VOLUME (UNITS)
14.2.12.3. AVERAGE SELLING PRICE (USD)
14.2.13 IDURSULFASE
14.2.13.1. MARKET VALUE (USD MILLION)
14.2.13.2. MARKET VOLUME (UNITS)
14.2.13.3. AVERAGE SELLING PRICE (USD)
14.2.14 GALSULFASE
14.2.14.1. MARKET VALUE (USD MILLION)
14.2.14.2. MARKET VOLUME (UNITS)
14.2.14.3. AVERAGE SELLING PRICE (USD)
14.2.15 ALDURAZYME
14.2.15.1. MARKET VALUE (USD MILLION)
14.2.15.2. MARKET VOLUME (UNITS)
14.2.15.3. AVERAGE SELLING PRICE (USD)
14.2.16 OTHER
14.3 GENE THERAPY
14.3.1 STRIMVELIS
14.3.1.1. MARKET VALUE (USD MILLION)
14.3.1.2. MARKET VOLUME (UNITS)
14.3.1.3. AVERAGE SELLING PRICE (USD)
14.3.2 VALOCTOCOGENE ROXAPARVOVEC
14.3.2.1. MARKET VALUE (USD MILLION)
14.3.2.2. MARKET VOLUME (UNITS)
14.3.2.3. AVERAGE SELLING PRICE (USD)
14.3.3 ETRANACOGENE DEZAPARVOVEC
14.3.3.1. MARKET VALUE (USD MILLION)
14.3.3.2. MARKET VOLUME (UNITS)
14.3.3.3. AVERAGE SELLING PRICE (USD)
14.3.4 VOLANESORSEN
14.3.4.1. MARKET VALUE (USD MILLION)
14.3.4.2. MARKET VOLUME (UNITS)
14.3.4.3. AVERAGE SELLING PRICE (USD)
14.3.5 PEGVALIASE
14.3.5.1. MARKET VALUE (USD MILLION)
14.3.5.2. MARKET VOLUME (UNITS)
14.3.5.3. AVERAGE SELLING PRICE (USD)
14.3.6 OTHER
14.4 SMALL MOLECULE-BASED THERAPY
14.4.1 METFORMIN
14.4.1.1. MARKET VALUE (USD MILLION)
14.4.1.2. MARKET VOLUME (UNITS)
14.4.1.3. AVERAGE SELLING PRICE (USD)
14.4.2 SULFONYLUREAS
14.4.2.1. MARKET VALUE (USD MILLION)
14.4.2.2. MARKET VOLUME (UNITS)
14.4.2.3. AVERAGE SELLING PRICE (USD)
14.4.3 DPP-4 INHIBITORS
14.4.3.1. SITAGLIPTIN
14.4.3.1.1. MARKET VALUE (USD MILLION)
14.4.3.1.2. MARKET VOLUME (UNITS)
14.4.3.1.3. AVERAGE SELLING PRICE (USD)
14.4.3.2. SAXAGLIPTIN
14.4.3.2.1. MARKET VALUE (USD MILLION)
14.4.3.2.2. MARKET VOLUME (UNITS)
14.4.3.2.3. AVERAGE SELLING PRICE (USD)
14.4.4 SGLT2 INHIBITORS
14.4.4.1. CANAGLIFLOZIN
14.4.4.1.1. MARKET VALUE (USD MILLION)
14.4.4.1.2. MARKET VOLUME (UNITS)
14.4.4.1.3. AVERAGE SELLING PRICE (USD)
14.4.4.2. EMPAGLIFLOZIN
14.4.4.2.1. MARKET VALUE (USD MILLION)
14.4.4.2.2. MARKET VOLUME (UNITS)
14.4.4.2.3. AVERAGE SELLING PRICE (USD)
14.4.5 EZETIMIBE
14.4.5.1. MARKET VALUE (USD MILLION)
14.4.5.2. MARKET VOLUME (UNITS)
14.4.5.3. AVERAGE SELLING PRICE (USD)
14.4.6 TETRAHYDROBIOPTERIN
14.4.6.1. MARKET VALUE (USD MILLION)
14.4.6.2. MARKET VOLUME (UNITS)
14.4.6.3. AVERAGE SELLING PRICE (USD)
14.4.7 D-PENICILLAMINE
14.4.7.1. MARKET VALUE (USD MILLION)
14.4.7.2. MARKET VOLUME (UNITS)
14.4.7.3. AVERAGE SELLING PRICE (USD)
14.4.8 TRIENTINE
14.4.8.1. MARKET VALUE (USD MILLION)
14.4.8.2. MARKET VOLUME (UNITS)
14.4.8.3. AVERAGE SELLING PRICE (USD)
14.4.9 OTHER
14.5 SUBSTRATE REDUCTION THERAPY
14.5.1 ZAVESCA
14.5.1.1. MARKET VALUE (USD MILLION)
14.5.1.2. MARKET VOLUME (UNITS)
14.5.1.3. AVERAGE SELLING PRICE (USD)
14.5.2 GALAFOLD
14.5.2.1. MARKET VALUE (USD MILLION)
14.5.2.2. MARKET VOLUME (UNITS)
14.5.2.3. AVERAGE SELLING PRICE (USD)
14.5.3 OTHER
14.6 CELLULAR TRANSPLANTATION
14.6.1 HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT)
14.6.1.1. MARKET VALUE (USD MILLION)
14.6.1.2. MARKET VOLUME (UNITS)
14.6.1.3. AVERAGE SELLING PRICE (USD)
14.6.2 ISLET CELL TRANSPLANTATION
14.6.2.1. MARKET VALUE (USD MILLION)
14.6.2.2. MARKET VOLUME (UNITS)
14.6.2.3. AVERAGE SELLING PRICE (USD)
14.6.3 PANCREATIC ISLET CELL ENCAPSULATION
14.6.3.1. MARKET VALUE (USD MILLION)
14.6.3.2. MARKET VOLUME (UNITS)
14.6.3.3. AVERAGE SELLING PRICE (USD)
14.6.4 NEURAL STEM CELL TRANSPLANTATION
14.6.4.1. MARKET VALUE (USD MILLION)
14.6.4.2. MARKET VOLUME (UNITS)
14.6.4.3. AVERAGE SELLING PRICE (USD)
14.7 OTHERS
15 GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET, BY APPLICATION
15.1 OVERVIEW
15.2 LYSOSOMAL STORAGE DISEASES
15.2.1 GAUCHER'S DISEASE
15.2.2 FABRY DISEASE
15.2.3 POMPE DISEASE
15.2.4 HURLER - SCHEIE
15.2.5 SANFILIPO A
15.2.6 OTHERS
15.3 DIABETES
15.4 OBESITY
15.5 INHERITED METABOLIC DISORDERS
15.6 HYPERCHOLESTEROLEMIA
15.7 GALACTOSEMIA
15.8 MAPLE SYRUP URINE DISEASE (MSUD)
15.9 MEDIUM-CHAIN ACYL-COA DEHYDROGENASE (MCAD) DEFICIENCY
15.1 CONGENITAL ADRENAL HYPERPLASIA (CAH)
15.11 OTHER
16 GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET, BY THERAPY TYPE
16.1 OVERVIEW
16.2 MONOTHERAPY
16.3 COMBINATION THERAPY
17 GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET, BY DRUG TYPE
17.1 OVERVIEW
17.2 BRANDED
17.2.1 CEREZYME
17.2.2 VPRIV
17.2.3 REPLAGAL
17.2.4 GLIPIZIDE
17.2.5 ATORVASTATIN
17.2.6 CYSTAGON
17.2.7 LARONIDASE
17.2.8 ALDURAZYME
17.2.9 CYSTADANE
17.2.10 OTHER
17.3 GENERICS
18 GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTARTION
18.1 OVERVIEW
18.2 ORAL
18.2.1 CAPSULE
18.2.2 TABLETS
18.2.3 OTHER
18.3 PARENTERAL
18.3.1 INTRAVENOUS
18.3.2 SUBCUTANEOUS
18.3.3 INTRAMUSCULAR
18.4 OTHER
19 GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET, BY PATIENT TYPE
19.1 OVERVIEW
19.2 PEDIATRIC
19.3 ADULT
19.3.1 MALE
19.3.2 FEMALE
19.4 GERIATRIC
19.4.1 MALE
19.4.2 FEMALE
20 GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET, BY END USER
20.1 OVERVIEW
20.2 HOSPITALS
20.2.1 PUBLIC
20.2.2 PRIVATE
20.3 SPECIALITY CLINICS
20.4 HOME CARE
20.5 AMBULATORY SURGICAL CENTERS
20.6 OTHERS
21 GLOBAL. METABOLIC DISORDERS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL
21.1 OVERVIEW
21.2 DIRECT TENDER
21.3 RETAIL PHARMACIES
21.3.1 HOSPITAL PHARMACIES
21.3.2 RETAIL PHARMACIES
21.3.3 ONLINE PHARMACIES
21.3.4 OTHER
21.4 OTHERS
22 GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET, BY REGION
GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
22.1 NORTH AMERICA
22.1.1 U.S.
22.1.2 CANADA
22.1.3 MEXICO
22.2 EUROPE
22.2.1 GERMANY
22.2.2 U.K.
22.2.3 ITALY
22.2.4 FRANCE
22.2.5 SPAIN
22.2.6 RUSSIA
22.2.7 SWITZERLAND
22.2.8 TURKEY
22.2.9 BELGIUM
22.2.10 NETHERLANDS
22.2.11 DENMARK
22.2.12 SWEDEN
22.2.13 POLAND
22.2.14 NORWAY
22.2.15 FINLAND
22.2.16 REST OF EUROPE
22.3 ASIA-PACIFIC
22.3.1 JAPAN
22.3.2 CHINA
22.3.3 SOUTH KOREA
22.3.4 INDIA
22.3.5 SINGAPORE
22.3.6 THAILAND
22.3.7 INDONESIA
22.3.8 MALAYSIA
22.3.9 PHILIPPINES
22.3.10 AUSTRALIA
22.3.11 NEW ZEALAND
22.3.12 VIETNAM
22.3.13 TAIWAN
22.3.14 REST OF ASIA-PACIFIC
22.4 SOUTH AMERICA
22.4.1 BRAZIL
22.4.2 ARGENTINA
22.4.3 REST OF SOUTH AMERICA
22.5 MIDDLE EAST AND AFRICA
22.5.1 SOUTH AFRICA
22.5.2 EGYPT
22.5.3 BAHRAIN
22.5.4 UNITED ARAB EMIRATES
22.5.5 KUWAIT
22.5.6 OMAN
22.5.7 QATAR
22.5.8 SAUDI ARABIA
22.5.9 REST OF MEA
22.6 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
23 GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET, SWOT AND DBMR ANALYSIS
24 GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET, COMPANY LANDSCAPE
24.1 COMPANY SHARE ANALYSIS: GLOBAL
24.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
24.3 COMPANY SHARE ANALYSIS: EUROPE
24.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
24.5 MERGERS & ACQUISITIONS
24.6 NEW PRODUCT DEVELOPMENT & APPROVALS
24.7 EXPANSIONS
24.8 REGULATORY CHANGES
24.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
25 GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET, COMPANY PROFILE
25.1 NOVO NORDISK A/S
25.1.1 COMPANY OVERVIEW
25.1.2 REVENUE ANALYSIS
25.1.3 GEOGRAPHIC PRESENCE
25.1.4 PRODUCT PORTFOLIO
25.1.5 RECENT DEVELOPMENTS
25.2 SANOFI S.A.(GENZYME)
25.2.1 COMPANY OVERVIEW
25.2.2 REVENUE ANALYSIS
25.2.3 GEOGRAPHIC PRESENCE
25.2.4 PRODUCT PORTFOLIO
25.2.5 RECENT DEVELOPMENTS
25.3 BOEHRINGER INGELHEIM GMB
25.3.1 COMPANY OVERVIEW
25.3.2 REVENUE ANALYSIS
25.3.3 GEOGRAPHIC PRESENCE
25.3.4 PRODUCT PORTFOLIO
25.3.5 RECENT DEVELOPMENTS
25.4 ELI LILLY AND COMPANY
25.4.1 COMPANY OVERVIEW
25.4.2 REVENUE ANALYSIS
25.4.3 GEOGRAPHIC PRESENCE
25.4.4 PRODUCT PORTFOLIO
25.4.5 RECENT DEVELOPMENTS
25.5 MERCK KGAA
25.5.1 COMPANY OVERVIEW
25.5.2 REVENUE ANALYSIS
25.5.3 GEOGRAPHIC PRESENCE
25.5.4 PRODUCT PORTFOLIO
25.5.5 RECENT DEVELOPMENTS
25.6 AMGEN, INC.
25.6.1 COMPANY OVERVIEW
25.6.2 REVENUE ANALYSIS
25.6.3 GEOGRAPHIC PRESENCE
25.6.4 PRODUCT PORTFOLIO
25.6.5 RECENT DEVELOPMENTS
25.7 ASTRAZENECA PLC
25.7.1 COMPANY OVERVIEW
25.7.2 REVENUE ANALYSIS
25.7.3 GEOGRAPHIC PRESENCE
25.7.4 PRODUCT PORTFOLIO
25.7.5 RECENT DEVELOPMENTS
25.8 ACTELION PHARMACEUTICALS LTD.
25.8.1 COMPANY OVERVIEW
25.8.2 REVENUE ANALYSIS
25.8.3 GEOGRAPHIC PRESENCE
25.8.4 PRODUCT PORTFOLIO
25.8.5 RECENT DEVELOPMENTS
25.9 SHIRE (TAKEDA PHARMACEUTICALS)
25.9.1 COMPANY OVERVIEW
25.9.2 REVENUE ANALYSIS
25.9.3 GEOGRAPHIC PRESENCE
25.9.4 PRODUCT PORTFOLIO
25.9.5 RECENT DEVELOPMENTS
25.1 ABBVIE, INC.
25.10.1 COMPANY OVERVIEW
25.10.2 REVENUE ANALYSIS
25.10.3 GEOGRAPHIC PRESENCE
25.10.4 PRODUCT PORTFOLIO
25.10.5 RECENT DEVELOPMENTS
25.11 BIOCON LTD.
25.11.1 COMPANY OVERVIEW
25.11.2 REVENUE ANALYSIS
25.11.3 GEOGRAPHIC PRESENCE
25.11.4 PRODUCT PORTFOLIO
25.11.5 RECENT DEVELOPMENTS
25.12 BIOMARIN PHARMACEUTICAL, INC.
25.12.1 COMPANY OVERVIEW
25.12.2 REVENUE ANALYSIS
25.12.3 GEOGRAPHIC PRESENCE
25.12.4 PRODUCT PORTFOLIO
25.12.5 RECENT DEVELOPMENTS
25.13 BRISTOL-MYERS SQUIBB COMPANY
25.13.1 COMPANY OVERVIEW
25.13.2 REVENUE ANALYSIS
25.13.3 GEOGRAPHIC PRESENCE
25.13.4 PRODUCT PORTFOLIO
25.13.5 RECENT DEVELOPMENTS
25.14 CIPLA, INC.
25.14.1 COMPANY OVERVIEW
25.14.2 REVENUE ANALYSIS
25.14.3 GEOGRAPHIC PRESENCE
25.14.4 PRODUCT PORTFOLIO
25.14.5 RECENT DEVELOPMENTS
25.15 CYMABAY THERAPEUTICS, INC.
25.15.1 COMPANY OVERVIEW
25.15.2 REVENUE ANALYSIS
25.15.3 GEOGRAPHIC PRESENCE
25.15.4 PRODUCT PORTFOLIO
25.15.5 RECENT DEVELOPMENTS
25.16 AMICUS THERAPEUTICS, INC.
25.16.1 COMPANY OVERVIEW
25.16.2 REVENUE ANALYSIS
25.16.3 GEOGRAPHIC PRESENCE
25.16.4 PRODUCT PORTFOLIO
25.16.5 RECENT DEVELOPMENTS
25.17 ULTRAGENYX PHARMACEUTICAL INC.
25.17.1 COMPANY OVERVIEW
25.17.2 REVENUE ANALYSIS
25.17.3 GEOGRAPHIC PRESENCE
25.17.4 PRODUCT PORTFOLIO
25.17.5 RECENT DEVELOPMENTS
25.18 REGENERON PHARMACEUTICALS INC.
25.18.1 COMPANY OVERVIEW
25.18.2 REVENUE ANALYSIS
25.18.3 GEOGRAPHIC PRESENCE
25.18.4 PRODUCT PORTFOLIO
25.18.5 RECENT DEVELOPMENTS
25.19 SANGAMO THERAPEUTICS
25.19.1 COMPANY OVERVIEW
25.19.2 REVENUE ANALYSIS
25.19.3 GEOGRAPHIC PRESENCE
25.19.4 PRODUCT PORTFOLIO
25.19.5 RECENT DEVELOPMENTS
25.2 ORCHARD THERAPEUTICS INC
25.20.1 COMPANY OVERVIEW
25.20.2 REVENUE ANALYSIS
25.20.3 GEOGRAPHIC PRESENCE
25.20.4 PRODUCT PORTFOLIO
25.20.5 RECENT DEVELOPMENTS
25.21 LEADIANT BIOSCIENCES, INC.
25.21.1 COMPANY OVERVIEW
25.21.2 REVENUE ANALYSIS
25.21.3 GEOGRAPHIC PRESENCE
25.21.4 PRODUCT PORTFOLIO
25.21.5 RECENT DEVELOPMENTS
25.22 UNIQURE N.V.
25.22.1 COMPANY OVERVIEW
25.22.2 REVENUE ANALYSIS
25.22.3 GEOGRAPHIC PRESENCE
25.22.4 PRODUCT PORTFOLIO
25.22.5 RECENT DEVELOPMENTS
25.23 BLUEBIRD BIO, INC.
25.23.1 COMPANY OVERVIEW
25.23.2 REVENUE ANALYSIS
25.23.3 GEOGRAPHIC PRESENCE
25.23.4 PRODUCT PORTFOLIO
25.23.5 RECENT DEVELOPMENTS
25.24 GENETHON
25.24.1 COMPANY OVERVIEW
25.24.2 REVENUE ANALYSIS
25.24.3 GEOGRAPHIC PRESENCE
25.24.4 PRODUCT PORTFOLIO
25.24.5 RECENT DEVELOPMENTS
25.25 AGTC
25.25.1 COMPANY OVERVIEW
25.25.2 REVENUE ANALYSIS
25.25.3 GEOGRAPHIC PRESENCE
25.25.4 PRODUCT PORTFOLIO
25.25.5 RECENT DEVELOPMENTS
*NoTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST
26 RELATED REPORTS
27 CONCLUSION
28 QUESTIONNAIRE
29 ABOUT DATA BRIDGE MARKET RESEARCH
